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Myosins have been implicated in various motile processes, including organelle translocation, ion-channel gating,
and cytoskeleton reorganization. Different members of the myosin superfamily are responsible for syndromic and
nonsyndromic hearing impairment in both humans and mice. MYH14 encodes one of the heavy chains of the class
II nonmuscle myosins, and it is localized within the autosomal dominant hearing impairment (DFNA4) critical
region. After demonstrating that MYH14 is highly expressed in mouse cochlea, we performed a mutational screening
in a large series of 300 hearing-impaired patients from Italy, Spain, and Belgium and in a German kindred linked
to DFNA4. This study allowed us to identify a nonsense and two missense mutations in large pedigrees, linked to
DFNA4, as well as a de novo allele in a sporadic case. Absence of these mutations in healthy individuals was tested
in 200 control individuals. These ﬁndings clearly demonstrate the role of MYH14 in causing autosomal dominant
hearing loss and further conﬁrm the crucial role of the myosin superfamily in auditive functions.
Hereditary hearing loss is caused, in 150% of cases, by
mutations in single genes, including myosins, connexins,
transcription factors, potassium channels, and other cel-
lular components that play an important function in ear
cells (see Hereditary Hearing Loss Homepage). Different
members of the myosin superfamily are responsible for
syndromic and nonsyndromic hearing impairment trans-
mitted as an autosomal dominant or recessive trait. Phy-
logenetic analyses have identiﬁed 18 distinct classes of
myosins: 17 classes represent unconventional myosins,
and class II includes conventional muscle and nonmuscle
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myosins (Berg et al. 2001). Among unconventional myo-
sins, mutations in the MYO7A gene are responsible for
type 1B Usher syndrome (MIM 276903), a syndromic
deafness combined with retinitis pigmentosa and vestibu-
lar abnormalities. MYO7A is also implicated in two non-
syndromic forms of dominant and recessive hearing loss,
DFNA11 and DFNB2, as well as in a strain of deaf mice
called “shaker-1” (Liu et al. 1997; Weil et al. 1997). The
MYO6 gene is mutated in human DFNA22 and in the
Snell’s waltzer mouse (Avraham et al. 1995; Melchionda
et al. 2001). The MYO15A gene is mutated in human
DFNB3 and in mouse shaker-2 (Probst et al. 1998;Wang
et al. 1998). Most recently, it has been shown that nor-
mal hearing in humans requires myosin IIIA (MYO3A)
and myosin IA (MYO1A), which are implicated in two
nonsyndromic forms of hearing impairment, DFNB30
and DFNA48, respectively (Walsh et al. 2002; Donaudy
et al. 2003).
The conventional myosins of class II consist of 15
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Figure 1 RT-PCR of the Myh14 gene in mouse cochlea. Speciﬁc
oligonucleotides C1F (5′-AGCATTGGAAGAGGAGTCCC-3′) andC2R
(5′-GCTCCAGTCGTTCTACAGC-3′), spanning coding exons 26–30,
were used to detect the expression of Myh14 in mouse cochlea RNA,
as well as in two mouse cell lines, B16 (melanoma) and ES cells.
Cochlea RNA was kindly provided by K. Avraham (Tel Aviv). In brief,
it has been prepared from inner ears dissected out of the temporal
bones of mice at embryonic day (E) 14, E16, E18, and P0. Negative
control was performed without cDNA aliquot in the reaction.Marker:
1-kb DNA ladder (BioLabs).
genes, including 6 skeletal-muscle myosin heavy chains,
2 cardiac myosin heavy chains, a smooth-muscle myosin
heavy chain, and 3 nonmuscle myosin heavy chains
II (NMHC IIA, NMHC IIB, and NMHC IIC) (Berg
et al. 2001). The three nonmuscle myosins are encoded
by the MYH9, MYH10, and MYH14 genes located on
chromosomes 22q11.2, 17p13.3, and 19q13.3, respec-
tively (Simons et al. 1991; Leal et al. 2003). Among
nonmuscle myosins, MYH9 was the only gene known to
be responsible for a human pathology, including four au-
tosomal dominant diseases reported elsewhere as May
Hegglin anomaly and as Sebastian, Fechtner, and Epstein
syndromes (Seri et al. 2003). Patients with these diseases
have congenital macrothrombocytopenia and aggregates
of NMHC IIA in neutrophils. During life, they can de-
velop deafness, nephritis, and cataract. The same gene
is also mutated in a family affected by nonsyndromic
hearing impairment, DFNA17 (MIM 603622) (Lalwani
et al. 2000).
It is interesting that MYH14 is located within a can-
didate region in which a nonsyndromic autosomal domi-
nant form of hearing impairment, DFNA4, has been
mapped independently in two unrelated families (Chen
et al. 1995; Mirghomizadeh et al. 2002). The two can-
didate regions partly overlap, deﬁning a critical region
of ∼4 Mb between markers D19S412 and D19S246.
Therefore, the MYH14 gene was considered a strong
candidate for hearing loss. First, we ascertained its ex-
pression in cochlea, using a speciﬁc anti-NMHC IIC an-
tibody. We then performed mutational screening of the
gene in a large series of 300 sporadic or familial hearing-
impaired patients from Italy, Belgium, and Spain. The
identiﬁcation of one nonsense and three missense mu-
tations clearly indicates a fundamental contribution of
MYH14 to autosomal dominant hearing loss.
To determine whether the MYH14 gene is expressed
in cochlea, we ﬁrst assayed for its expression in mice.
Total RNA from mouse cochlea, from mouse melanoma
cell line B16 (Chirivi et al. 1994), and embryonic stem
(ES) TVB2 cells, was reverse transcribed to perform RT-
PCR. The correct fragment length of 768 bp was am-
pliﬁed from cochlear cDNA (ﬁg. 1).
The NMHC IIC protein was detected in mouse coch-
lear neonatal sections (postnatal day [P0]) by use of
polyclonal antibodies raised against mouse C-terminal
NMHC IIC (Golomb et al. 2004). High expression was
detected in the organ of Corti and the stria vascularis,
as well as in cells of the cochlear duct, such as Hensen
and Claudius cells, external sulcus cells, and epithelium
of the spiral prominence (ﬁg. 2). It is interesting that low
or no expression of NMHC IIC was detected in the
Reissner membrane and spiral ligament, in contrast with
the MYH9 expression in the latter structures in the rat
(Lalwani et al. 2000). It is also interesting that no ex-
pression was detectable in vestibular epithelia (data not
shown), in agreement with phenotypic ﬁndings in pa-
tients (see below).
An overall number of 300 subjects were analyzed for
mutations in the MYH14 gene. Inclusion criteria were:
(a) absence of the most common mutations within the
GJB2 gene, (b) sensorineural hearing loss, and (c) nor-
mal tympanometric evaluation. All subjects underwent
a physical examination, including otoscopy; pure-tone
audiometry with air and bone conduction performed at
125, 250, 500, 1,000, 2,000, 4,000, and 8,000 Hz with
a Beltone 2000 audiometer; and tympanometry. The se-
ries includes subjects with a variable degree of hearing
loss, ranging from mild to profound, and with a variable
age at onset, ranging from congenital to late onset. Fa-
milial records were available, in most cases. Themajority
of patients came from central and southern Italy (200),
whereas 48 and 52 were from Spain and Belgium, re-
spectively. A large German family (Tu¨-N) that made pos-
sible the mapping of the DFNA4 locus to a 2.7-Mb map
segment in 19q13.33 was also included in the screening
(M.P., personal communication). After receipt of in-
formed consent, peripheral blood was obtained from all
subjects, and DNA was isolated from blood leukocytes
according to standard methods.
An overall number of 40 primer pairs were designed
to amplify the 40 coding exons of the MYH14 gene, in-
cluding the splice sites (PCR primer sequences and
conditions available on request). All amplicons were
screened by DHPLC on a WAVE Nucleic Acid Fragment
Analysis SystemHSM (Transgenomic), according to sup-
plier protocols. DHPLC data analysis was based on a
subjective comparison of sample and reference chro-
matograms. PCR products showing an abnormal chro-
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Table 1
Mutations Identiﬁed in the MYH14 Gene
Mutationa Exon
Effect
on Protein Protein Domain
C20A 1 S7X Motor domain
G1126T 9 G376C Motor domain
C2176A 16 R726S Tail
C2926T 22 L976F Tail
a GenBank accession number NM_024729. (The
A of the ﬁrst methyonine is referred to as nucleotide
1.)
Figure 2 Immunohistochemistry of NMHC IIC in mouse neonatal cochlea. Gelatin tissues at P0 were sectioned (10 mm) and ﬁxed with
4% paraformaldehyde. A, Negative control obtained using only biotin-conjugated immunoglobulin G secondary antibodies. B, Section im-
munolabeled with anti-NMHC IIC antibodies (Buxton et al. 2003; Golomb et al. 2004), revealing a high expression in the cells surrounding
the scala media. The insert is enlarged in panel C. sv p scala vestibuli; sm p scala media; st p scala tympany; rm p Reissner’s membrane;
oc p organ of Corti; stv p stria vascularis. No expression in the vestibular epithelia has been detected (data not shown). Scale barsp 20 mm.
matographic proﬁle were directly sequenced on an au-
tomated sequencer (ABI 3100 [Perkin Elmer]).
The mutational screening of the MYH14 gene allowed
us to identify one nonsense and three missensemutations
(table 1). The ﬁrst mutation is a CrA nucleotide change
at position 20, which replaces a serine residue at position
7 with a stop codon (S7X) (ﬁg. 3A). This mutation was
detected in the German 4-generation kindred Tu¨-N that
mapped to the DFNA4 locus and deﬁned a 2.7-Mb can-
didate region containing the MYH14 gene (M.P., un-
published data). In this pedigree, the affected individuals
show a progressive sensorineural hearing impairment
that starts in the 1st or 2nd decade of life and leads to
severe-to-profound hearing loss in the 4th decade of life.
A GrT nucleotide change was detected at position
1126 of the cDNA, leading to a glycinercysteine amino
acid substitution at position 376 (G376C) in the motor
domain (data not shown). It was detected in a 9-year-
old Italian patient affected by a moderate bilateral sen-
sorineural hearing loss without vestibular involvement.
There was no family history of hearing loss, and neither
Figure 3 MYH14 nonsense and missense mutations. A, Sequence data of the nonsense S7X mutation. B, Pedigree of the Belgian family
with the R726S mutation and results showing its presence after AlwNI restriction-enzyme digestion. Haplotypes were constructed with markers
around the MYH14 gene. Shared haplotypes are indicated with rectangles. MWM p molecular weight marker; N p normal. C, Pedigree of
the Italian family with the L976F mutation and results showing sequence data in the proband (III:2) and in a healthy member (II:3).
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Table 2
Nucleotide Substitutions
Identiﬁed in the Coding Region
of the MYH14 Gene
Nucleotide
Variant Exon
Effect
on Protein
T474C 2 Silent
A796G 6 I266V
C1128T 9 Silent
C1731T 13 Silent
C1863T 14 Silent
C2082T 15 Silent
G1506A 21 Silent
A2895G 21 Silent
G4722A 32 Silent
A4676G 32 N1559S
A5307G 36 Silent
G5406T 37 Silent
T5745C 39 Silent
A5889T 40 Silent
NOTE.—The following intronic
variants have also been detected:
IVS244GrA, IVS519GrA,
IVS78GrC, IVS813CrT,
IVS127GrC, IVS2111TrC,
and IVS259CrT.
Figure 4 ClustalW (European Bioinformatics Institute) alignment of the amino acid sequences of smooth muscle and nonmuscle myosins
of class II; sequence alignments for MYH14 missense mutations. The residues mutated in NMHC IIC and their conservation across species are
underlined. Hs p Homo sapiens; Rn p Rattus norvegicus; Mm p Mus musculus.
parent had the G376C mutation. Repeated analysis in
the proband conﬁrmed the presence of this mutated al-
lele, which affects a residue highly conserved across spe-
cies (ﬁg. 4), was absent in control chromosomes and is,
therefore, described as a de novo alteration. Paternity
has been conﬁrmed using a panel of highly informa-
tive microsatellite markers.
Another CrA change affecting nucleotide 2176 was
detected in a large Belgian kindred. This change leads
to substitution of a highly conserved arginine residuewith
serine at position 726 (R726S) (ﬁg. 4). The presence of
the mutation can be easily detected by PCR and sub-
sequent cleavagewith the restriction endonucleaseAlwNI.
We constructed haplotypes for a 3-cM region surround-
ing the MYH14 gene, including the mutation and a total
of ﬁve dinucleotide markers (ﬁg, 3B).
We found that all affected family members shared the
same haplotype from markers D19S879 (centromeric) to
D19S601 (telomeric), indicating that this family showed
linkage with the DFNA4 region and that the mutation
cosegregated with hearing impairment. Patients show a
mild-to-moderate progressive hearing loss without ves-
tibular involvement.
Finally, the sequence from the affected member (III-
2) of a small Italian family (ﬁg. 3C) displayed the het-
erozygous nucleotide transition CrT at position 2926
in exon 22. This leads to the amino acid substitution
L976F affecting the NMHC IIC tail. Although leucine
and phenylalanine are both nonpolar residues, this par-
ticular position appears to be evolutionarily conserved in
the species available in the databases (ﬁg. 4). The patient
inherited the mutation from his hearing-impaired father
(II-4). Sequence analysis conﬁrmed the absence of this
mutation in the healthy members of the pedigree. Af-
fected individuals present with a mild-to-moderate bi-
lateral sensorineural hearing impairment without ves-
tibular symptoms.
The presence of these mutated alleles was tested on
200 normal chromosomes of individuals from the same
geographical area as that of patients. None of the alleles
was detected in any normal chromosome. We also de-
tected two polymorphic variants, I266V and N1559S,
12 synonymous substitutions, and 7 intronic nucleotide
substitutions (table 2). Since these latter changes do not
create putative cryptic splice sites and/or did not seg-
regate with deafness (data not shown), they have been
excluded as causative mutations for deafness in our co-
hort of patients.
The MYH14 gene was an excellent candidate for hear-
ing impairment because of its chromosomal location
within the DFNA4 critical region and its high expression
in the cochlea. One nonsense and three missense hetero-
zygous mutations have been identiﬁed in 4 patients be-
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longing to a cohort of 300 affected individuals from
different European countries. Apart from patients car-
rying the nonsense allele who presented a profound hear-
ing loss from the 4th decade of life, patients with the
missense mutations were affected by sensorineural bi-
lateral hearing loss of variable degree, usually ranging
from moderate to severe. This ﬁnding might indicate a
genotype-phenotype correlation, in which a more-severe
clinical course is most likely to be associated with re-
duced levels of NMHC IIC.
It is interesting that one of the three missensemutation
is a de novo allele altering an evolutionarily conserved
residue. This mutated allele was never detected in
healthy control individuals, and paternity was conﬁrmed
at molecular levels. The patient is the only affectedmem-
ber of his family, as negative records (i.e., audiological
and clinical data) have been obtained for all members.
These ﬁndings strongly support the pathogenic role of
G376C. Two other missense mutations were detected in
families affected by autosomal dominant hearing loss.
Similar to most of the MYH9 mutations (Seri et al. 2003),
the majority of mutations identiﬁed in the MYH14 gene
comprises amino acid substitutions, suggesting that they
might exert a dominant negative effect. For the three
missense mutations found, there is a remarkable con-
servation of the residues’ positions across species, which
probably highlights their functional importance in the
peptide (ﬁg. 4). However, a functional analysis of all mis-
sense mutations will deﬁnitively prove their molecular
mechanisms on pathogenesis.
Myosins of class II are hexameric enzymes composed
of two heavy chains and two pairs of light chains. Di-
merization of the heavy chains yields a polar structure.
The N-termini form two globular heads with actin- and
ATP-binding domains required for motor activity,
whereas the a-helical C-termini form a single rodlike
tail, which allows the molecules to polymerize into bi-
polar ﬁlaments in both muscle and nonmuscle cells (Sell-
ers 2000). Besides the well-characterized role of myosin
in contraction and force production in muscles, little
is known about the speciﬁc functional role of nonmuscle
myosins, although they are likely to participate in mo-
tility, cytokinesis, phagocytosis,maintenance of cell shape,
and organelle/particle trafﬁcking.
The NMHC IIC myosin has only recently been char-
acterized, and information on its biological role is very
limited. The expression pattern deﬁned in human and
mouse tissues showed that the gene is ubiquitously ex-
pressed at higher levels in adults than during develop-
ment (Buxton et al. 2003; Leal et al. 2003; Golomb et
al. 2004). In the mouse cochlea, with the exception of
the Reissner membrane, the protein is localized in all cells
of the scala media wall, with a relatively higher level in
the organ of Corti and the stria vascularis. It is remark-
able that the NMHC IIC distribution is different from
the expression of the MYH9 (Lalwani et al. 2000),
which immunolocalizes speciﬁcally in outer cells of the
organ of Corti, spiral ligament, and Reissner membrane.
Although the role of both nonmuscle myosins in the coch-
lear cells remains unclear, taken together, the expression
data indicate that different physiopathogenetic mecha-
nisms are probably implicated in hearing impairment
owing to mutations in the MYH9 and MYH14 genes.
Finally, the identiﬁcation of four different mutations
suggests that the MYH14 gene distinctly contributes to
autosomal dominant cases of hearing impairment. As a
matter of fact, only a few genes among those so far
described present with mutations in more than one single
family (see Hereditary Hearing Loss Homepage). Ad-
ditional population-based and functional studies are re-
quired to determine the precise contribution of MYH14
to deafness.
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